Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 12, 2024 07:10 ET
|
Zenas BioPharma
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy- ...
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
November 12, 2024 07:05 ET
|
Zenas BioPharma
-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas...
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
November 07, 2024 07:05 ET
|
Zenas BioPharma
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the...
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
September 19, 2024 16:15 ET
|
Zenas BioPharma
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development...
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
September 12, 2024 22:37 ET
|
Zenas BioPharma
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development...
Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
July 01, 2024 07:00 ET
|
Zenas BioPharma
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based...
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
May 07, 2024 07:00 ET
|
Zenas BioPharma
Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors Proceeds to...
Zenas BioPharma Nomeia Patricia Allen para o Conselho Diretor
March 06, 2024 18:59 ET
|
Zenas BioPharma
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias voltadas...
ゼナス･バイオファーマ (Zenas BioPharma)、パトリシア・アレン (Patricia Allen) を取締役会に任命
March 06, 2024 18:59 ET
|
Zenas BioPharma
マサチューセッツ州ウォルサム発, March 07, 2024 (GLOBE NEWSWIRE) --...
Patricia Allen rejoint le Conseil d’administration de Zenas BioPharma
March 06, 2024 18:59 ET
|
Zenas BioPharma
WALTHAM, Massachusetts, 07 mars 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, un laboratoire biopharmaceutique d’envergure mondiale déterminé à rejoindre les leaders du développement et de la...